Just old stuff I'm afraid.

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jan 20, 2009 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced an update on corporate activities. Since providing additional data analysis for its TERMS Phase IIb clinical trial in October, Opexa has been actively engaged in discussions to partner Tovaxin®, its lead therapy and novel ...

http://www.businesswire.com/news/opexa/ ... 0006096/en


THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced an update on corporate activities. Since providing additional data analysis for its TERMS Phase IIb clinical trial in October, Opexa has been actively engaged in discussions to partner Tovaxin®, its lead therapy and novel ...

Hey y'all--

I have the first THREE mails out to study sites (Ohio). My state list is okay, as far as that goes, but not all these addresses are complete enough to include certain people (study coordinators). And sometimes even zip codes.

So... if you please, PM me the complete address of your own study site--and a name, if available, so we can get this ball rolling.

From snowy and blowy Cincinnati,
ME the Pain

Something I hadn’t seen before on the OPEXA website (official-dom in italics, my comments NOT):

http://www.opexatherapeutics.com/biocentury_10102008.pdf

November 10, 2008 Reprint from BIOCENTURY

Banking on Safety—by Erin McCallister Senior Writer

Even though its Tovaxin missed the primary endpoint in a Phase IIb trial to treat relapsing-remitting multiple sclerosis, Opexa Therapeutics Inc. thinks the autologous stem cell vaccine has a chance in RRMS. The company’s confidence is based in part on a post hoc analysis of secondary ...

Hi,
I am an italian girl, i was diagnosed in 1999.
I would like to know when Tovaxin will end Phase II trial.
Does someone know if this drug will start phase III?
And when? Do you think there will be some centre in Europe starting phase III?
thank you for your reply!!

Get your cyber blue pencils at the ready and have fun! If I don't have to do TOO many re-writes, I (we) might get this out by week's end!

God Bless Us One and All...

My full address
Date
Their full address w/their exciting titles, of course

Dear Dr./Mr./Ms. So-and-So:

My name is Jane ____ (not “the Pain” because this is VERY official, dontcha know?) and I was a patient in the Tovaxin clinical study ...

Hey gang,

I thought it would be interesting to have a topic where we post how the termination appointment went as well as what meds/treatment did you decide to switch to. My termination appointment is tomorrow so I will update you then.

Take care,
Mike

..

I just got a call from my coordinator and Opexa is suspending Tovaxin.
Thats all I know at this point.
Will have to research what my next adventure will be.

Its been a wild ride, for sure!

Opexa to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw’s 10th Annual Healthcare Conference. The conference will be held November 10-12, 2008, ...